CN Patent

CN112675178A — 预防和治疗血小板增多的癌症患者中的转移性疾病

Assigned to Quick Da Pharmaceutical Co ltd · Expires 2021-04-20 · 5y expired

What this patent protects

本申请涉及预防和治疗血小板增多的癌症患者中的转移性疾病。特别地，本申请涉及抗巨核细胞剂阿那格雷(anagrelide)或其治疗活性代谢物在预防和/或治疗表现出副肿瘤性血小板增多的癌症患者中的转移性疾病中的用途。

USPTO Abstract

本申请涉及预防和治疗血小板增多的癌症患者中的转移性疾病。特别地，本申请涉及抗巨核细胞剂阿那格雷(anagrelide)或其治疗活性代谢物在预防和/或治疗表现出副肿瘤性血小板增多的癌症患者中的转移性疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN112675178A
Jurisdiction
CN
Classification
—
Expires
2021-04-20
Drug substance claim
No
Drug product claim
No
Assignee
Quick Da Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.